• Medifast Inc MED.N, MED is expected to show a fall in quarterly revenue when it reports results on February 18 for the period ending December 31 2024

• The Baltimore Maryland-based company is expected to report a 40.2% decrease in revenue to $114.25 million from $191.02 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on November 4 2024, for the period ended December 31, was for revenue between $100.00 million and $120.00 million.

• ​LSEG's mean analyst estimate for Medifast Inc is for a loss of 16 cents per share. The company's EPS guidance on November 4 2024, for the period ended December 31, was between $-0.65 and $-0.10

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Medifast Inc is $16.50​, above​ its last closing price of $16.03. ​​​

This summary was machine generated February 14 at 21:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)